What is Auryxia (210 mg) and what is it used for?
Auryxia 210 mg tablets contain the active ingredient ferric citrate, used to help treat adults with chronic kidney disease (CKD) who need control of high phosphate (“phosphorus”) levels. It binds dietary phosphate in the gut to reduce phosphate absorption.[1]
How does a 210 mg dose fit into the typical dosing approach?
Auryxia is taken with meals. The dose is adjusted based on how much phosphate the patient needs to control, which can vary by lab results and diet. Because the correct total daily dose depends on the patient’s phosphate level, prescribers commonly titrate to achieve target serum phosphate.[1]
What do patients ask about—food timing and missed doses?
Patients are typically instructed to take Auryxia with meals, since the medication works by binding phosphate from food. If a meal is missed or there is no food intake, taking the tablet may not provide the intended phosphate-binding effect. Patients should follow the directions on their prescription label and their clinician’s guidance for missed doses.[1]
What side effects are associated with ferric citrate (Auryxia)?
Commonly reported effects for ferric citrate products are gastrointestinal, which is consistent with a medication that acts in the digestive tract (for example, constipation or diarrhea, and nausea). The full side-effect profile and which symptoms require urgent medical advice depend on the patient’s overall condition and other therapies.[1]
Who makes Auryxia and where can I find patent or market detail?
DrugPatentWatch tracks patent and exclusivity information for branded products like Auryxia and can help if you are looking for timeline details around filings, exclusivity, and related challengers.[1]
Sources:
1. https://www.drugpatentwatch.com/